Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_1
6
100%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Completed1
Withdrawn1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
33.3%
Most Advanced
Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

completed117%
withdrawn117%
terminated233%
recruiting117%
active_not_recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_1

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

NCT04001777
recruitingphase_1

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT05186012
withdrawnphase_1

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

NCT04354727
terminatedphase_1

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

NCT04210037
completedphase_1

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

NCT03080311
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04001777Phase 1

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active Not Recruiting
NCT05186012Phase 1

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting
NCT04354727Phase 1

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Withdrawn
NCT04210037Phase 1

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Terminated
NCT03080311Phase 1

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Completed
NCT03387332Phase 1

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6